CD24 and breast cancer: To further validate the clinical utility of iSUF, we have processed serum samples from 10 metastatic breast cancer (BC) patients and demonstrated the presence of HER2, CD24 and miR21 biomarkers at significantly higher levels compared to healthy controls (p < 0.05).